Sweat-Powered Sticker Turns Drinking Cup Into a Health Sensor
UC San Diego engineers have created a battery‑free electronic sticker that attaches to drinking cups and measures a user’s vitamin C levels from fingertip sweat. The biofuel cell harvests sweat‑derived electricity to power a hydrogel‑based sensor, which wirelessly sends results to a laptop within minutes. The prototype costs only a few cents per unit, dramatically undercutting the typical $50 laboratory test. Researchers aim to expand the platform to track additional nutrients and integrate with smartphones.
FDA, After Turbulent Year, Leaves Drugmakers Guessing on Its Direction
The FDA’s leadership turmoil has intensified under Commissioner Marty Makary, with the agency cycling through multiple heads of its CDER and CBER centers in just over a year. Public‑facing comments from senior officials have sparked sharp stock moves, most notably...
Engineers Create Hydrogels to Monitor Activity in the Body
Engineers at Washington University in St. Louis have developed granular bioelectronic hydrogels composed of PEDOT:PSS microparticles that can be injected, 3D‑printed, or spread over tissue. The material behaves like a liquid under force but solidifies into a porous, paste‑like matrix,...
GSK Reports the NMPA Approval of Exdensur (Depemokimab) for Severe Asthma
GlaxoSmithKline’s biologic Exdensur (depemokimab) received approval from China’s National Medical Products Administration as an add‑on maintenance therapy for patients aged 12 and older with severe eosinophilic asthma. The approval is based on Phase III SWIFT‑1 (382 participants) and SWIFT‑2 (380 participants)...
Oric to Advance Prostate Cancer Drug to Phase 3, but Combo Choice Raises Doubts
Oric Pharmaceuticals announced that its PRC2 inhibitor will move into a registrational Phase 3 trial for prostate cancer after reporting encouraging safety and disease‑control signals in a Phase 1b study. The company plans to evaluate the drug both as a...
Frontier Medicines Grants Ex-China Rights of FMC-220 to LG Chem
Frontier Medicines has granted LG Chem an exclusive global license to develop and commercialize its covalent p53 Y220C activator FMC-220 outside Greater China, while retaining full rights within that region. LG Chem will manage regulatory filings, global clinical development, and...
Patients Know Best and Heartfelt Technologies Collaborate to Accelerate Clinical Trial Recruitment
Patients Know Best teamed with Heartfelt Technologies to automate recruitment for the Innovate UK‑funded HF‑TRACK trial, enrolling 16 participants in just four weeks—a 135% increase over the trial’s average rate. The partnership leveraged PKB’s coded health‑record data to display a...
Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study
Ultragenyx Pharmaceutical reported that its Phase 3 Enh3ance trial of DTX301, an AAV8 gene therapy for ornithine transcarbamylase deficiency, achieved an 18% reduction in 24‑hour plasma ammonia versus placebo at Week 36, with average ammonia levels staying within normal range. Eight of...
Soleno Therapeutics (SLNO) Still Appears Attractive Despite Slower U.S. Launch Ramp Projections
Oppenheimer kept an Outperform rating on Soleno Therapeutics but lowered its price target to $80 from $110, signaling a potential upside of more than 166%. Wells Fargo trimmed its target slightly to $110 while remaining Overweight. Both firms highlighted a slower‑than‑expected...
Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress
Mineralys Therapeutics (NASDAQ:MLYS) received a renewed Buy rating from Bank of America Securities, which lifted its price target to $51 from $46 after the company reported fourth‑quarter results. The firm highlighted progress on lorundrostat, an aldosterone synthase inhibitor, noting the...
Yes, GLP-1s Are Changing What Food People Buy — Here's How
GLP‑1 drugs such as Ozempic and Wegovy are prompting measurable changes in grocery purchasing patterns. A Danish study of 1,177 adults, covering nearly two million transactions, found that users bought foods with slightly lower calories, sugar, carbohydrates and saturated fat,...
ACC 2026: Sotatercept Shows Signal in CpcPH-HFpEF at Lower Dose
At the 2026 ACC Scientific Session, the phase‑II CADENCE trial showed that sotatercept (WINREVAIR) reduced pulmonary vascular resistance in adults with combined post‑ and precapillary pulmonary hypertension linked to HFpEF (CpcPH‑HFpEF). The study randomized 164 patients, median age 75, to...
Six Biotech Companies in Berlin to Watch in 2026
Berlin’s biotech sector is gaining global traction, highlighted by six innovative firms. 3B Pharmaceuticals secured a Novartis licensing deal for its FAP‑2286 radioligand and is collaborating on an astatine‑211 candidate. Ariceum Therapeutics dosed its first patient in a phase 1/2 trial...
Conductive Hydrogel Can Sense Oxygen and Guide Cell Behaviour
Researchers have created a conductive hydrogel, PEDOT:sGAGh, that mimics the extracellular matrix while sensing oxygen and electrically regulating growth‑factor release. By polymerizing less than 1 wt % PEDOT within a sulfated glycosaminoglycan hydrogel, they achieved a 95 wt % water‑rich, soft material with dual...
Symeres and Ambagon Collaborate for Colorectal Cancer Molecules
Symeres has partnered with Ambagon Therapeutics to evaluate molecular‑glue compounds for colorectal cancer. The collaboration will leverage Symeres’ in‑vitro assays, surface‑plasmon resonance kinetics, and fluorescence microscopy to characterize ternary‑complex formation and downstream pathway effects. Symeres will also profile each candidate...
Symeres and Ambagon Collaborate for Colorectal Cancer Molecules
Symeres has partnered with Ambagon Therapeutics to evaluate Ambagon’s molecular glue candidates for colorectal cancer. The collaboration will use Symeres’ in‑vitro assays, surface plasmon resonance, fluorescence microscopy and a 102‑cell line panel to characterize ternary complex kinetics and downstream pathway...
STAT+: The Biotech Scorecard for the Second Quarter: 23 Stock-Moving Events to Watch
STAT’s quarterly biotech scorecard lists 23 upcoming events that could move biotech stocks in Q2 2026. Highlights include Phase 3 results from Abivax’s obefazimod in ulcerative colitis and Allogene Therapeutics’ interim data on its cema‑cel CAR‑T therapy for B‑cell lymphoma. The...
Lilly Moves Deeper Into Sleep Medicine with up to $7.8 Billion Centessa Deal
Eli Lilly announced a definitive agreement to acquire UK‑based Centessa Pharmaceuticals for up to $7.8 billion, paying $38 per share in cash and up to $9 per share in contingent milestones. The acquisition gives Lilly control of Centessa’s orexin‑receptor‑2 agonist pipeline,...
Anavex Updates Regulatory Strategy for Blarcamesine
Anavex Life Sciences has withdrawn its European Union marketing authorization application for blarcamesine and will collect additional data while maintaining dialogue with the European Medicines Agency. The company has concurrently submitted new data to the U.S. FDA to explore a...
Insilico Medicine, Lilly Partner on AI-Driven Drug Discovery Deal
Insilico Medicine and Eli Lilly have entered a partnership to use Insilico’s AI‑driven Pharma.AI platform for discovering new oral therapeutics across several disease areas. Lilly receives an exclusive worldwide license to develop, manufacture and commercialize the preclinical candidates, while Insilico secures...
New Data Show TrenibotE Safety in Repeat Treatments
Allergan Aesthetics presented new Phase 3 data on its investigational neurotoxin TrenibotE at the 2026 American Academy of Dermatology meeting. The open‑label study evaluated up to three repeat glabellar line treatments, confirming a consistent safety profile, no neutralizing antibodies, rapid onset...
Elidah Reports US FDA Clearance of Elitone for Men to Treat Post-Prostatectomy Urinary Incontinence
Elidah announced that the U.S. Food and Drug Administration has cleared its at‑home device, Elitone for Men, to treat urinary incontinence after prostate surgery. The non‑invasive system delivers neuromuscular stimulation to the pelvic floor for a 20‑minute daily session, eliminating...
3 Career Moves R&D Professionals Must Make in a Skills-Based, AI-Driven Economy
Biopharma R&D careers are shifting from title‑driven ladders to skills‑centric portfolios as AI automates routine tasks. Professionals must treat each role as an opportunity to acquire execution‑level capabilities, use generative AI to deepen scientific judgment, and continuously assess and market...
The Brave New World of Radiotherapeutics
Radiotherapeutics have moved from niche concepts to a burgeoning oncology platform, driven by unmet treatment gaps and the commercial breakthrough of Novartis' Pluvicto. Early data show Actinium‑225 delivering 45‑50% response rates in heavily pre‑treated prostate cancer, while Bayer's Xofigo adds...
AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure
AskBio, a Bayer subsidiary, announced that enrollment for its GenePHIT Phase 2 trial of the investigational gene therapy AB‑1002 has been completed, randomizing 173 patients with non‑ischemic cardiomyopathy and NYHA Class III heart‑failure symptoms. The trial, spanning 46 sites across North America...
The Deep-Tech Founder Using AI to Address Immunology Challenges
Camille Bouget, CEO and co‑founder of Scienta Lab, launched EVA, a multimodal AI platform designed to accelerate immunology drug development. The model helps R&D teams identify viable therapeutic targets, predict preclinical efficacy, and stratify patients for clinical trials. By applying...
How GLP-1 Is Impacting Food and Beverage Consumption in Australia
GLP-1 receptor agonists, originally developed for type‑2 diabetes, are rapidly being prescribed for weight management in Australia, with about 500,000 users today and projections that 10% of the population could be on the drugs by 2030. Their appetite‑suppressing effect is...
The Role of Ethical Oversight and Algorithmic Bias in Automated Pharmacovigilance
Pharmacovigilance is rapidly adopting machine learning, natural language processing, and automation to ingest, categorize, and prioritize adverse event reports, dramatically shrinking backlogs and accelerating signal detection. While these technologies deliver speed and scale, they also inherit reporting biases and can...
Antipsychotic-Like Effects of the Selective Rho-Kinase 2 Inhibitor KD025 in Genetic and Pharmacological Mouse Models of Schizophrenia
The selective ROCK2 inhibitor KD025 (belumosudil) demonstrated antipsychotic‑like activity in both genetic (Arhgap10 S490P/NHEJ) and pharmacological (methamphetamine and MK‑801) mouse models of schizophrenia. KD025 restored reduced spine density in the medial prefrontal cortex and rescued deficits in a touchscreen visual‑discrimination...
Jupiter Neurosciences Inc (JUNS) Q4 2025 Earnings Call Transcript
Jupiter Neurosciences reported total product sales of $2.8 billion in 2025, a 22% year‑over‑year increase driven by INGREZZA and the debut of CRENESSITY. INGREZZA generated just over $2.5 billion, up 9% on volume growth, while CRENESSITY posted $300 million in its first full...
From Free Rider to Innovator: How China Became a Global Pharmaceutical Powerhouse
China has transformed from a pharmaceutical free rider into a leading innovator, largely after the 2016 National Reimbursement Drug List (NRDL) reform. The policy slashed prices by 50‑60% while guaranteeing near‑universal coverage, prompting a five‑fold rise in annual clinical trials...
Reactivation of Dormant Regulatory T Cells Alleviates Asthma Symptoms in Mice
Researchers at Henan Academy, Zhengzhou University and Shenzhen University demonstrated that activating the Dectin‑1 receptor on regulatory T cells (Tregs) can reverse their dormant, senescent state and restore anti‑inflammatory function. Using the small peptide KQS‑1, they epigenetically up‑regulated FOXP3 and...
Genetic Variants Involved in Rapid Immune Response Linked to Earlier Breast Cancer Onset in BRCA1 Carriers
Researchers identified damaging variants in innate immunity genes, especially those governing natural killer (NK) cell activation, as strong modifiers of breast cancer onset in women carrying the BRCA1 185delAG mutation. An analysis of 321 Ashkenazi Jewish carriers showed that these...
Shields and Bodyguards: Scientists Uncover the Hidden Defenses of a Deadly Childhood Cancer
University of Queensland researchers applied spatial multi‑omics to 27 neuroblastoma samples, creating high‑resolution maps that reveal a GPX4‑driven shield protecting tumor cells from ferroptosis and surrounding immune cells acting as "bodyguards." The study, published in Genome Medicine, identifies GPX4 as...
TYK2 Protein Suppresses Breast Cancer Metastasis by Sensing Extracellular Stiffness, Research Finds
Researchers at UC San Diego discovered that the inflammatory protein TYK2 acts as a metastasis suppressor in breast cancer by sensing extracellular matrix stiffness. On soft matrices, TYK2 remains on the cell membrane and blocks invasion, while stiff environments cause...
Dual-Target Strategy Shows Promise in Overcoming Drug Resistance in MCL
A recent preclinical study identified BIRC5 and MCL‑1 as co‑drivers of survival in mantle cell lymphoma (MCL) and demonstrated that simultaneous inhibition with YM155 and S63845 produces strong synergistic killing of cancer cells. The combination was effective across both treatment‑naïve...
Targeting Tumor Supporting Cells: Lipid Nanoparticles Advance CAR T Success in Pancreatic Cancer
Researchers at Penn Vet used lipid nanoparticles (LNPs) to deliver FAP‑CAR mRNA directly to patients' T cells, enabling in‑vivo engineering of CAR T cells that attack cancer‑associated fibroblasts in pancreatic ductal adenocarcinoma. In a preclinical mouse model, a single dose of...
A Startup Has Been Quietly Pitching Cloned Human Bodies to Transfer Your Brain Into
Stealth biotech startup R3 Bio, backed by billionaire investors, announced a fundraising round to develop non‑sentient monkey organ‑sack platforms for donor organs. Investigative reporting by MIT Technology Review revealed that the founders are also exploring the far more controversial concept...
Off-the-Shelf CAR T-Cell Therapy Granted Breakthrough Therapy Designation for Aggressive T-Cell Cancers
Soficabtagene geleucel (WU‑CART‑007), an off‑the‑shelf CRISPR‑engineered CAR‑T therapy, received FDA Breakthrough Therapy Designation for relapsed or refractory T‑cell leukemia and lymphoma. In a phase 1/2 trial of 28 patients, the drug achieved a 91% overall response rate and a 73% complete...
Using “Left-Handed” Proteins to Block Alzheimer’s
Kobe University researchers engineered a synthetic right‑handed (D) peptide that binds amyloid‑beta, the disordered protein driving Alzheimer’s plaques, and blocks its aggregation. In mouse brain cell cultures the mirror peptide restored cell viability to 100%, compared with 50% survival when...
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Nanobiotix posted full‑year 2025 results showing a revenue rebound to roughly $35.5 million and a net loss of $26 million, a 65% YoY improvement. The company secured a non‑dilutive royalty financing of up to $71 million, extending its cash runway to early 2028 with...
Frailty, Innovation, and the Future of Myeloma Treatment With Joseph Mikhael, MD
Joseph Mikhael, MD, highlights a dramatic shift in multiple myeloma care for older adults, driven by refined frailty assessments and the rise of targeted immunotherapies such as CAR‑T cells and bispecific antibodies. These advances have translated into higher survival rates...
New Sensor Could Allow MRIs to See Molecular-Level Changes
University of California, Santa Barbara researchers have engineered a genetically encoded, protein‑based sensor that lets magnetic resonance imaging capture molecular‑level activity inside cells. The modular system, called MAPPER, couples aquaporin water channels with interchangeable protein domains to generate MRI‑detectable signals...
Key Neurons Can Jumpstart Leg Movement After Spinal Injury
Researchers identified a rare subset of graft‑derived interneurons that can reconnect broken spinal circuits and trigger leg muscle activity in animal models of spinal cord injury. When these neurons were experimentally activated, 20‑30% of the subjects showed measurable leg movements,...
TippingPoint Raises $4.5M Seed to Drug Hidden Epigenetic Targets in Deadly Pediatric Brain Cancer
TippingPoint Biosciences announced a $4.5 million seed round led by SOSV and LKS Fund to advance its epigenetic drug discovery platform. The company targets protein‑protein interfaces within disease‑specific chromatin environments, aiming at sites traditionally deemed undruggable. Its inaugural program focuses on...
Turning Muscles Into Motors Gives Static Organs New Life
MIT researchers unveiled a myoneural actuator (MNA) that rewires sensory nerves to transform existing muscle into a fatigue‑resistant, computer‑controlled motor for paralyzed organs. In rodent models the MNA restored intestinal squeezing and mimicked residual calf muscle function while sending sensory...
Yuvezzi for Presbyopia Now Available in US
Tenpoint Therapeutics announced that Yuvezzi, the first FDA‑approved eye‑drop for presbyopia, is now commercially available in the United States. The formulation combines carbachol 2.75 % and brimonidine tartrate 0.1 % to induce pupil constriction within 30 minutes, providing up to ten hours...
Vanda’s Tradipitant Has Phase II Success but a Court Setback
Vanda Pharmaceuticals reported that its NK1‑receptor antagonist tradipitant achieved its primary endpoint in a Phase II trial for gastroparesis, showing a roughly 30% improvement in nausea scores versus placebo. The data suggest the drug could address a sizable unmet need in...
AI-Built Intrabodies Target Alzheimer’s Within
University of Essex researchers used artificial intelligence to redesign antibody fragments, creating "intrabodies" that remain stable inside human cells. By adjusting electrical charge, they converted 672 antibodies into intracellularly functional molecules that bind disease‑causing proteins linked to Alzheimer’s, Parkinson’s, Huntington’s...
Scientists Have Discovered an 'Achilles' Heel' In Deadly Superbugs
Scientists have identified pseudaminic acid, a sugar found only on the surface of certain Gram‑negative bacteria, as a vulnerable target. By synthesizing this sugar and creating monoclonal antibodies that bind it, researchers demonstrated in mice that the antibodies flag the...
